Active, not recruitingPhase 3NCT04951219
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Studying NON RARE IN EUROPE: Non-alcoholic fatty liver disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Madrigal Pharmaceuticals, Inc.
- Principal Investigator
- Rebecca Taub, MDMadrigal Pharmaceuticals, Inc.
- Intervention
- Resmetirom(drug)
- Enrollment
- 1000 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- Central Research Associates, Birmingham, Alabama, United States
- Arizona Liver Health - Chandler, Chandler, Arizona, United States
- East Valley Family Physicians, Chandler, Arizona, United States
- The Institute For Liver Health - Glendale, Glendale, Arizona, United States
- The Institute For Liver Health - Tucson, Tucson, Arizona, United States
- Adobe Gastroenterology, Tucson, Arizona, United States
- Arkansas Gastroenterology, North Little Rock, Arkansas, United States
- Fresno Clinical Research Center, Fresno, California, United States
- National Research Institute - Huntington Park, Huntington Park, California, United States
- Ruane Clinical Research Group, Los Angeles, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- National Research Institute - Los Angeles, Los Angeles, California, United States
- National Research Institute - Panorama City, Panorama City, California, United States
- San Fernando Valley Health Institute, West Hills, California, United States
- South Denver Gastroenterology - Swedish Medical Center Office, Englewood, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04951219 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-alcoholic fatty liver disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07335198A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European AncestryGlaxoSmithKline
- ACTIVE NOT RECRUITINGNANCT07366710Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PETRigshospitalet, Denmark
- RECRUITINGPHASE4NCT06449833Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLDZhujiang Hospital
- RECRUITINGNANCT06413069Effects of Almonds in Glucose-intolerant Adults (AGAMEMNON)Charite University, Berlin, Germany
- RECRUITINGNANCT06275906Influence of a Mediterranean Diet Combined With a Physical Activity Intervention, on NAFLD and Inflammation Parameters.Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
- RECRUITINGPHASE1NCT05979389Bicalutamide Therapy in Young Women With NAFLD and PCOSUniversity of California, San Francisco
- RECRUITINGNANCT06704321Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLDValbiotis
- ACTIVE NOT RECRUITINGNANCT06697977Effects of Phytosterol Supplementation on Liver Function and Inflammatory Status in Patients with Nonalcoholic Fatty Liver DiseaseUniversity of Jordan
See all trials for NON RARE IN EUROPE: Non-alcoholic fatty liver disease →